Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric selpercatinib for advanced RET-altered solid or primary CNS tumors
2023-507703-63-00Phase 2Authorised
- Sponsor
- Loxo Oncology
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of selpercatinib in Nonhematologic neoplasms and central nervous system tumor (2 arms), sponsored by Loxo Oncology. Primary endpoints: Frequency, severity and relatedness of TEAEs and SAEs, including DLTs and Objective response rate. Planned start Jun 2024; status: authorised.
02
Drugs
selpercatinib
03
Conditions
Nonhematologic neoplasmscentral nervous system tumor
Beyond the preview
Go deeper on 2023-507703-63-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507703-63-00.